KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Total Non-Current Liabilities rose 1311.96% to $4.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 billion, marking a year-over-year increase of 1311.96%. This contributed to the annual value of $4.2 billion for FY2025, which is 1311.96% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $4.2 billion for Q4 2025, which was up 1311.96% from $4.2 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $4.2 billion for Q3 2025, and its period low was $2.3 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $3.6 billion (2023), whereas its average is $3.4 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 14640.22% in 2021, then tumbled by 149.94% in 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $3.0 billion in 2021, then grew by 18.13% to $3.5 billion in 2022, then grew by 7.16% to $3.7 billion in 2023, then fell by 1.5% to $3.7 billion in 2024, then grew by 13.12% to $4.2 billion in 2025.
  • Its Total Non-Current Liabilities stands at $4.2 billion for Q4 2025, versus $4.2 billion for Q3 2025 and $3.9 billion for Q2 2025.